Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of Ritonavir
- 1 December 2002
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 3 (6), 493-501
- https://doi.org/10.1310/0873-bvdp-akay-445u
Abstract
Background: Protease inhibitors (PIs) are substrates for the P-glycoprotein (P-gp/170) encoded by the multi-drug resistance gene (MDR-1). HIV infection is associated with increased expression of P-gp. The role of MDR gene overexpression in clinical pharmacokinetics is not known. Method: We determined by HPLC, at trough and peak levels, the current PI concentrations in plasma (P) and in peripheral blood mononuclear cells (PBMCs) (intracellular concentration [IC]) from 49 HIV-infected patients receiving different treatment combinations: nelfinavir ([NFV] n = 12); indinavir ([IDV] n = 10); amprenavir ([APV] n = 5); ritonavir (RTV) 100 bid/IDV 800 mg bid (n = 6); RTV 400 bid/IDV 400 mg bid (n = 3); RTV 100 bid/saquinavir (SQV) 600 mg tid (n = 9); APV 600 bid/RTV 100 mg bid (n = 4). We determined the mean ratio of intracellular/plasma PI concentration for each treatment group. The MDR-1 gene expression was determined by a semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR). HIV viral load was simultaneously measured. Results: 49 patients (mean age 41 ± 8.7 years; mean CD4 cell count 418 [57-972]; mean HIV RNA 2.1 ± 0.8 log10) were included in the study. Patients who overexpressed the MDR-1 gene had significantly lower trough intracellular PI levels (p = .02) or lower intracellular accumulation of PI (p = .042). Patients treated with low-dose RTV in combined regimens with detectable RTV intracellular concentration showed lack of MDR-1 gene expression (p = .01). Patients with HIV RNA < 40 copies/mL had significantly higher RTV intracellular accumulation (p = .029). Conclusion: In HIV-infected patients, IC of PI is inversely correlated with MDR-1 gene overexpression. Undetectable viral load was associated with the use of low-dose RTV, probably linked to better intracellular accumulation of the drug. Nevertheless, further investigation is needed to confirm these results.Keywords
This publication has 28 references indexed in Scilit:
- Intracellular Accumulation of Human Immunodeficiency Virus Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2002
- Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trialThe Lancet, 1999
- Dossier médical informatisé pour les patients atteints d'infection par le VIH (ADDIS): l'expérience du Service des Maladies infectieuses du CHU de NiceMedecine Et Maladies Infectieuses, 1998
- HIV-1 Protease Inhibitors Are Substrates for theMDR1 Multidrug TransporterBiochemistry, 1998
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- HIV-1 protease inhibitors. A review for cliniciansJAMA, 1997
- P-Glycoproteins and Multidrug ResistanceAnnual Review of Pharmacology and Toxicology, 1996
- Molecular and Cellular Biology of Multidrug Resistance in Tumor CellsPublished by Springer Nature ,1991
- Human immunodeficiency virus I-induced expression of P-glycoproteinBiochemical and Biophysical Research Communications, 1990
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proceedings of the National Academy of Sciences, 1987